The authors discuss their 15 years of experience with use of noncholesterol sterols (NCS) when diagnosing heterozygous familial hypercholesterolemia (HFH) and the dietary and drug treatment of children and adolescents when lathosterol (Lat) and desmosterol (Des) as cholesterol synthesis precursors, and campesterol (Cam) and sitosterol (Sit) as cholesterol absorption precursors are included.
INTRODUCTION
All patients suffering from inherited hypercholesterolemias are burdened by premature cardio-or cerebrovascular events. Early identification of these inherited diseases allows administration of proper lifestyle and drug therapy as early as in childhood to prevent cardiovascular or cerebrovascular complications [1] [2] [3] [4] . There exist 2 types of disorders characterized by marked elevation of total cholesterol (TCh) and LDL-cholesterol (LDL-Ch): (1) familial hypercholesterolemias resulting from deficient LDL receptor proteins that cannot a) bind LDL (binding defects), b) internalize LDL (internalizing defects), c) disrupt the normal recycling of the LDLR (recycling defects), and (2) familial ligand defect of B-100 (FDB) hypercholesterolemia with missence mutation R3500Q.
It is a well-known fact that heterozygous familial hypercholesterolemia (HFH) with autosomal dominant *Address correspondence to this author at the Lipid Outpatient Clinic, Hospital Homolka, Prague (Ambulance pro poruchu lipidového metabolizmu, Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic; Tel:+420 603 440 013; E-mail: josef.hyanek@homolka.cz mode of inheritance (OMIM 143890) cannot be successfully treated by even a strict low-cholesterol diet (LCHD), and requires differentiated drug therapy. Recently, it has been finally accepted that pediatric HFH (boys from the age of 10 years and girls after first menstruation) require the same intensity of medical therapy as adults [5] [6] [7] [8] [9] [10] .
However, what are our options for early distinction between the so called "alimentary hypercholesterolemia" (AH) caused by overeating and an unhealthy lifestyle, which is most frequently encountered in our lipid clinic, and the most severe forms of HFH? The clinical symptoms in children being not yet as sufficiently developed as in adults, we can only use typical laboratory findings from the lipid spectrum supported by the molecular genetic examination of LDL-cholesterol receptors. Over the past 15 years, we have included noncholesterol sterols (NCS) in the testing, such as surrogate of cholesterol synthesis precursors and surrogate for cholesterol absorption in the testing.
Following the introduction of compulsory nationwide selective screening for hyperlipoproteinemia in the Czech Republic for children from high-risk families in their fifth and thirteenth year of life (since 1994), it is not only children of patients operated on in our hospital with a surgically documented risk of CVD who come to our metabolic clinic for further examination, but primarily children who have been identified with a range of different hypercholesterolemia symptoms in pediatric primary care settings [11] . These symptoms are subsequently differentiated and the required therapy is determined depending on the results-either LCHD in cases of AH or drug treatment in cases of HFH. Encouraged by the pioneering work of Hamilton, Miettinen, Kempen, Jones, Gylling [12] [13] [14] [15] [16] [17] [18] [19] [20] , and the promising latest research outcomes [21] [22] [23] , we have attempted to combine the standard lipid marker examination with the most easily available markers of cholesterol synthesis precursors-lathosterol (Lat) and desmosterol (Des)-, and the cholesterol absorption markers-campesterol (Cam) and beta-sitosterol (Sit)-for better hypercholesterolemia differentiation. (for NCS structures and simplified metabolism scheme see Figure 1a, 
b).
From a large cohort of pediatric and adolescent patients classified into groups according to the etiology of their hypercholesterolemia, we have till now observed important diagnostic and therapeutic dependencies sometimes similar to observations of Noto et al. or Hedman et al., which are presented below [24, 25] . The basic characteristics of the cohorts investigated are shown in Table 1 .
PATIENTS DEFINITION AND METHODS

Out
The LCHD was defined as 1992 NCEP-Ped Step II diet (<300 mg/d cholesterol in natural food) [26] . The "Alimentary Hypercholesterolemia" was determined on the basis of a lipid spectrum assessment, pedigree analysis, low risk of CVD in the family, and evaluation of a submitted two-week food journal, which was analyzed for nutrient content and cholesterol intake (mg/d) by the Ostrasoft Co. (1992) software programme [27] . According to recommendations by Rifkind, deJong, and Wiegman [5, 6, 28] , individual cholesterol tolerance was respected so as for TCh blood levels not to increase over 4.8 mmol/l.
Medical treatment involves the use of simvastatinZocor (MSD) in individual doses of 5-20 mg/d-, which has been successfully combined with ezetimibe- Ezetrol (MSD) in individual doses of 5-10 mg/d-over the past 10 years [5, 6, 9, 10] . During the two-month summer vacations, when the patients are usualy not available for monitoring and drug therapy, the drug treatment is often insufficiently observed, and the only remaining treatment is LCHD.
Monitoring of the diet and drug treatment is ensured by biochemical and immunological testing of lipid markers at 3-6 month intervals (depending on tha patient's compliance); levels of NCS, lipid soluble vitamins, sex hormones and trace elements in 6-month intervals. Height and weight are recorded using a software programme, secondary signs of sex maturation are registered according to Tanner and Goldstein [29] on each visit to the clinic. Performed annually, skinfold measurements are taken by the Best caliper, and IMT is measured using a VigmedSound device.
The routine biochemical and classical lipid spectrum (TCh colorimetric assay, HDL immunoassay, LDL direct immunoassay, TAG enzymatically) is determined using a Synchron Beckman Coulter LX 20; haematological spectrum by means of an Advia 120 Bayer; apo Al and apo B nephelometrically using an Immage; apo E polymorphism is measured by molecular genetic analysis; sexual hormone levels are determined with the IRMA method using a Stratec SR300; trace elements using a GT-AAS Varian; lipid soluble vitamins by means of HPLC with UV detection; vitaminD 3 with the RIA technique using a Multicrystal Berthold LB211; vitamin B6 using a Chromsystem; holotranscobalamin using an Abbot AXIM; and betacarotene by means of HPLC.
The following DNA analyses of genes for LDLreceptors and FDB (familial ligand-defective ApoB) are performed: direct DNA analysis, sequential analysis of exon 4 and 5, and analysis of deletions and duplications of the LDL-R gene and the entire region using the Multiplex Ligation Probe Amplification method, carried out through the goodwill of the Genetic Laboratory, Centre of Cardiovascular and Transplantation Surgery, Brno (MedPed project Czech National Coordinator, MUDr. T. Freiberger, PhD.) [30] . PCSK9 genes are not sequenced. The first degree relatives of HFH probands with identified gene mutations undergo DNA sequencing regardless of the LDL-cholesterol plasma levels.
Plasma NCS were determined first by GC following Phillips et al. [31] , later using the Theunissen [32] modification by means of a GC/MS Finnigan Mat 120B: internal standard epicoprostenal, CV <10%. The values of detectable lanosterol are very low without any possible diagnostic use. According to our practical experience and a longitudinal evaluation of the NCS levels, Des essentially follows in lower concentrations the Lat values, and Sit follows Cam values in a similar way: we have retained only these two markers in routine testing over the recent years and found them to be sufficient to register both cholesterol synthesis and phytosterol absorption.
The overall lipid extraction from the serum samples was performed using the Folch method [44] . First, the inner standard of epicholesterol (5 g) was added to the serum sample (0.9 ml). Methanol (0.9 ml) was added, and the whole mixture was agitated for 15 minutes. The extraction was done using chloroform (2 x 0.9 ml) while adding water solution of NaCl. The mixture was then centrifuged (at 200 g) for 10 minutes.
The lipid saponification was performed using the modified Thompson and Merola method [45] . Following evaporation of chloroform ethanol with 3% pyrogalol (8ml) was added to the lipid extract sample. The preparation was briefly mixed by hand, and KOH (0.5 ml, 1.28g/ml) solution was added. The saponification (30 min. at 88ºC) was performed following mixing and sonification of each sample. Cyclohexan (20 ml) and distilled water (12 ml) were added to each sample and the content was agitated. After centrifugation (at 200 g) the upper layer of cyclohexan was transferred into a vial, and evaporated under a nitrogen stream (approx. 65ºC).
Another step in the preparation of samples for GC/MS was their extraction derivatization using methanol-methyl chloroformate-pyridine. The reason was derivatization of sterols while separating the neutral lipid fraction from polar lipids. The derivatization was performed using the modified Hu ek Method [46] .
The extracted compounds were then analysed on the Focus GC with ITQ 700 ion trap mass spectrometer (manufactured by Thermo Electron Corporation) heated to 200°C. TR-1 column (30 m length, 0.25 mm internal diameter, 0.25 μm film of dimethyl polysiloxane) was used for separation. The ion source was operated in the electron ionisation mode (70 eV, 20 A) and the mass spectra were obtained using the ion trap operating in a SIM scan mode.
For expression of NCS serum values in this paper absolute values are used in μmol/l, as well as in μmol/l divided by total cholesterol in mmol/l x 100 as ratios, which according to Miettinen and Kempen better express the true NCS balance [12, 13] . 
Statistical Analysis
Statistical analysis was performed using MedCalc Version 8.1.1. 1 (Belgium). The basic statistical parameters included mean or median calculation (95% CI), number of elements in sample, maximum and minimum values, and relevant standard deviations. The normal distribution of the set was tested using the D'Agostino-Pearson test. For graphical comparison of patient groups Box-and-Whisker plots were used with the median and 25-75 percentil.
Paired t-test was used to compare the two independent means of NCS measured values and lipid metabolites during treatment. The difference was significant with values <0.05.
RESULTS
The individual cohorts of the children and adolescents under survey are basically characterized in Table 1 . The average NCS results for the group of 84 healthy school-age children used as reference values are given in Table 2 . Values for the healthy subjects are dominated by Cam, followed by Sit, while Lat and Des levels are lower. Despite the slightly lower levels in the youngest children, there is not much variance in the overall values between the healthy children and healthy adults. Children with HFH who have been on longitudinal LCHD, with which they often arrive at the outpatient lipid clinic, have higher levels of Lat and Des; Cam and Sit are also increased because the mothers usually enrich the LCHD with plant sterol margarines (Table 3, Figure 2a, 2b) .
In the group of children with documented LDL-R mutations, the increase in Lat and Des is greater than in the group of children with hypercholesterolemia where LDL-receptor deficiency has not been confirmed. Statins administrated in effective doses reduce TCh as well as Lat and Des levels (Figure 3) only been observed in few patiens. Combined treatment of statin with ezetimibe has to date produced the most effective decrease in both Lat and Des along with decreased TCh, while the Cam and Sit are also reduced (Figure 4a, 4b, 4c ). Children with AH do not have elevated levels of Lat, Des compared to HFH (Table 4, Figure 2a, 2b) .
In 30 child patients we could observe the "typical changes" in plasmatic Lat levels where the LCHD and targeted drug therapy were applied as shown in the graph in Figure 6 .
Our explanation is that during vacations the children are often without proper parental control for drug treatment, and thus usually only the LCHD is observed, which results in immediate Lat level increase.
Example of typical curves for Lat and other NCS during dietary and medical treatment in a 12-year homozygous female patient with FDB are shown in Figure 7 .
DISCUSSION
Every doctor working in a lipid clinic certainly has experience with the failure of LCHD in the treatment of HFH even when the parents comply with this treatment. We have all also encountered strict mothers or grandmothers who apply even stricter LCHD (200mg/d) than necesssary (leading more often than not to protein deficiency) trying to protect their children from the risk of the vascular failure they have experienced among their closest relatives, and whose attempts result in reduced growth as indicated by the children's growth curves. On the other hand, we see gullible mothers, and especially grandmothers, accompanying typically "overfed children" with TCh and TAG levels of 8-12 mmol/l, who only follow television advertising or clamorous leaflets offering "guaranteed" dietary products from domestic and foreign companies. We have therefore enlarged the range of markers for the differential diagnosis of hypercholesterolemias in order to simplify the system as much as possible and avoid harming the children.
A lot has been publicized about metabolism, physiological and pathobiochemical findings of NCS, esp. in connection with CVD, but little research is still available on the practical experience with its daily use [21, 23, 25] . In our decision-making concerning treatment in our clinic we have been so far most helped by Lat levels. The compensatory increase of Cam and Sit in statin therapy postulated by Miettinen, Descamps, Sudhop, Santosa, Hedman and al. [17, 18, 21, 22, 33, 34] have been observed only in few patients because the doses of statin used in combined therapy with ezetimibe in our children were mostly below 20 mg/d. However, some children cannot be clearly classified as belonging to any of the above mentioned groups based upon their first metabolic evaluation, and they maintain enormously high Lat values or high Cam values during various types of treatment. These are probably the types of patients described a long time ago by Katan et al. as "hyperresponders or hyporesponders" [35] .
However, we do agree with the recommendation of Miettinen et al. that effective statin therapy is mainly observed in the "synthetizer" type patients with high levels of Lat and Des, whereas ezetimibe treatment is more effective in the "absorber" type patients with high Cam and Sit. [17-19, 21, 23] . The combination of ezetimibe and statin is the most effective and least intrusive form of medical treatment, which fully corresponds with Sudhop's observations [36] . LCHD continues to be reserved primarily for AH, as well as for patients with mixed dyslipidemia, where no molecular genetic examination is yet available or the lipid laboratory spectrum does not allow for successful differentiation.
The possible correlation between low cholesterol synthesis of Lat and high absorption of Cam as seen by Weingartner and other authors in patiens proving the high risk of CVD could not be assessed in our children patiens with HFH [17, 37, 38, 39] .
It should be noted that phytosterols are also atherogenic substances and their increased intake is just as harmful to our health as high levels of cholesterol [40, 41] .
Given the existence of around 1,000 known mutations of LDL-Rs with different functional capacities for cholesterol internalization (from 5 to 70%) and also given the proven influence of other risk factors, such as high Lp (a) >1000 mg/l, or adverse polymorphism of apo E 3/4 and 4/4, it is not at all surprising to find such a wide range of hypercholesterolemic patients with diverse reactions to any treatment. The sample size of patients appearing too small to give such cathegorical conlusions, however, it will be necessary in the future to increase the number of patients, complete the methodology, compare practical experience, standardize the testing and verify the observations of different authors so that the discovered value of NCS can really be of practical daily use to clinic doctors, as recommended by MacKay , Thompson et al. [39, 42, 43] . o for checking whether the patient is actually taking the recommended medication and for verification of the actual intake of food enriched with plant sterol esters.
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